Silent suppression for Antisense
Wednesday, 15 October, 2008
Preclinical trials of Antisense Therapeutics’ [ASX: ANP] ATL1101 candidate have been shown to suppress human prostate tumour growth in animal models.
ATL1101 suppressed the growth of human tumours in mice that had been implanted with human prostate cancer sells.
The treatment slowed down the cancerous cells' transition to the most dangerous form of prostate cancer, castration-resistant prostate cancer [CRPC].
The study was conducted with the assistance of Martin Gleave, the director of the Prostate Centre at Vancouver General Hospital.
This is the first known demonstration of the efficacy of RNA-silencing IGF-I receptor drugs in prostate cancer models.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
